Nephrology

Barratt discusses the potential of targeting the alternative pathway for controlling inflammation and the significance of the new APPLAUSE-IgAN data.

Although the intervention did not reduce risk of CKD progression versus standard care, it addressed barriers to care and increased patients’ exposure to ACEi/ARBs.

Using the National Institutes of Health Toolbox Cognition Battery, results showed greater cognitive dysfunction across certain domains based on sex and CKD stage.

RUBY-3 findings support povetacicept’s ability to induce remission, reduce UPCR, stabilize renal function, and resolve hematuria in patients with IgAN.

Findings call attention to the risk of complications in patients with CKD and UACR <30 mg/g, highlighting the dangers of elevated albuminuria even in the normoalbuminuric range.

Results suggest low-dose corticosteroids in combination with leflunomide are more efficacious for improving urine protein excretion with better safety than full-dose corticosteroids.

Our March 2024 month in review highlights HCPLive’s top coverage of the latest news in nephrology, ranging from new CKD research and KDIGO guidelines to recent IgAN data.

Both high blood pressure and triglycerides were identified as risk factors for IgAN, although high blood pressure was deemed to have the most direct influence.

In this episode, Neuen talks about the FLOW trial, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies.

Findings underscore the importance of considering both the serum IgA/C3 ratio and glomerular C3 staining in the management and treatment of IgAN.

Previous reports suggest poor and unchanging rates of deceased kidney donation, though use of a recent metric for deaths compatible with donation yielded positive trends from 2003-2021.

Urinary miR-92a-3p, miR-425-5p, and miR-185-5p were significantly increased in patients with IgAN and were all associated with tubular atrophy/interstitial fibrosis.

Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.

The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease is an update to the KDIGO 2012 CKD Guideline.

A greater patient-to-patient care technician ratio was associated with increased mortality and hospitalization with lower rates of waitlisting and transplantation among patients receiving in-center hemodialysis.

Baseline kidney function, AKD severity, and post-AKD kidney function were identified as important factors for predicting outcomes in patients with acute kidney injury requiring dialysis.

Findings reveal a 20% mortality rate in an Eastern European cohort, primarily due to cardiovascular diseases and linked to an absence of RASi use, among other factors.

Results of the systematic review point to significant evidence gaps in most cardiovascular risk management interventions for patients with CKD, especially those with stages 4 to 5.

Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.

Use of corticosteroids with supportive therapy reduced proteinuria but was associated with adverse effects and did not impact time to ESKD versus supportive therapy alone.

Our February 2024 month in review spotlights news in IgAN identification and management as well as recent research about various factors impacting renal care outcomes in different patient populations.

Results identified mesangial IgM deposition as an independent risk factor for ESKD in patients with IgAN, particularly in advanced disease stages.

Younger gestational age, lower birthweight, and a more severe initial AKI episode were identified as risk factors for recurrent AKI, which was linked to extended hospitalization.

Findings suggest segregated residential and transplant center neighborhoods contribute to racial disparities in access to living donor kidney transplantation.

The incidence of KRT for primary glomerular disease-induced kidney failure was greatest for IgA nephropathy and focal segmental glomerulosclerosis.